Response to oral bisphosphonates in subgroups of younger and older postmenopausal women

Journal of Women's Health

Volumn 19, Issue 3, 2010, Pages 491-497

  Stovall, Dale W ^a   Beard, Mary K ^b   Barbier, Suzanne ^c   Chen, Erluo ^d   Rosenberg, Elizabeth ^d   De Papp, Anne E ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b Avenues Women's Center   (United States)

^c Women's Clinical Research Center   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGE FACTORS; AGED; ALENDRONATE; ANALYSIS OF VARIANCE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FEMUR; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 77950231788     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2009.1438     Document Type: Article

References (20)

1. National Osteoporosis Foundation. Pocket guide to prevention and treatment of osteoporosis.: National Osteoporosis Foundation, Washington, DC 2002.
2. Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res 2000;54 (Suppl 1):58-63.
3. Gehlbach SH, Fournier M, Bigelow C. Recognition of osteoporosis by primary care physicians. Am J Public Health 2002;92:271-273.
4. Bjarnason NH, Alexandersen P, Christiansen C. Number of years since menopause: Spontaneous bone loss is dependent but response to hormone replacement therapy is independent. Bone 2002;30:637-642.
5. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: A longitudinal study. Osteoporos Int 2002;13:105-112.
6. Ahlborg HG, Johnell O, Nilsson BE, Jeppsson S, Rannevik G, Karlsson MK. Bone loss in relation to menopause: A prospective study during 16 years. Bone 2001;28:327-331.
7. Recker R, Lappe J, Davies KM, Heaney R. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 2004;19:1628-1633.
8. Siris ES, Brenneman SK, Barrett-Connor E, et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50- 99: Results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 2006;17:565-574.
9. Uygur D, Sengul O, Bayar D, Erdinc S, Batioglu S, Mollamahmutoglu L. Bone loss in young women with premature ovarian failure. Arch Gynecol Obstet 2005;273:17-19.
10. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541.
11. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082.
12. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352.
13. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
14. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333-340.
15. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 2005;20:141-151.
16. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006;91:2631-2637.
17. Reid DM, Hosking D, Kendler D, et al. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: Results of FACTS-International. Clin Drug Invest 2006;26: 63-74.
18. Ried DM. European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Osteoporosis Int. 2006;17:S1-124.
19. Epstein S. Is cortical bone hip? What determines cortical bone properties? Bone 2007;41:S3-S8.
20. McClung MR, Wasnich RD, Hosking DJ, et al. Prevention of postmenopausal bone loss: Six-year results from the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab 2004;89:4879-4885.